Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 29.12 mg (equivalent: tapentadol, qty 25 mg) - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; purified talc; macrogol 6000; macrogol 400; titanium dioxide; iron oxide yellow; iron oxide red - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Ireland - English - HPRA (Health Products Regulatory Authority)

grünenthal ltd - tapentadol hydrochloride equivalent to free base - film coated tablet - 75 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

grünenthal ltd - tapentadol hydrochloride equivalent to free base - film coated tablet - 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

grünenthal ltd - tapentadol hydrochloride equivalent to free base - film coated tablet - 100 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

grünenthal ltd - tapentadol hydrochloride equivalent to free base - tablet prolonged release - 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

grünenthal ltd - tapentadol hydrochloride equivalent to free base - tablet prolonged release - 100 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

grünenthal ltd - tapentadol hydrochloride equivalent to free base - tablet prolonged release - 150 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

grünenthal ltd - tapentadol hydrochloride equivalent to free base - tablet prolonged release - 200 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 291.2 mg (equivalent: tapentadol, qty 250 mg) - tablet, modified release - excipient ingredients: iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; macrogol 6000; lactose monohydrate; hypromellose; magnesium stearate; purified talc; iron oxide black; titanium dioxide; colloidal anhydrous silica - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 232.96 mg (equivalent: tapentadol, qty 200 mg) - tablet, modified release - excipient ingredients: iron oxide yellow; hypromellose; magnesium stearate; colloidal anhydrous silica; iron oxide red; lactose monohydrate; titanium dioxide; purified talc; microcrystalline cellulose; macrogol 6000; propylene glycol - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.